CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8,038 enrolled
Drug / intervention
Harbinger Health Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05435066
NCT05435066N/ACompleted

Cancer ORigin Epigenetics-Harbinger Health - Collection of Blood and Tissue Samples From Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test

Harbinger Health·observational·Posted Jun 28, 2022·Updated Jul 29, 2025

In Brief

An observational study evaluating Harbinger Health Test for Cancer. Completed, enrolled 8,038 participants across 128 sites.

Detailed Summary

This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 28, 2022
Enrollment StartJun 21, 2022
Primary CompletionJun 11, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.0 years ago

Interventions

Harbinger Health Testother

This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year